- About this Journal
- Abstracting and Indexing
- Aims and Scope
- Annual Issues
- Article Processing Charges
- Articles in Press
- Author Guidelines
- Bibliographic Information
- Citations to this Journal
- Contact Information
- Editorial Board
- Editorial Workflow
- Free eTOC Alerts
- Publication Ethics
- Reviewers Acknowledgment
- Submit a Manuscript
- Subscription Information
- Table of Contents
Journal of Biomedicine and Biotechnology
Volume 2006 (2006), Article ID 74539, 5 pages
Tau Phosphorylation, Aggregation, and Cell Toxicity
Centro de Biología Molecular “Severo Ochoa”, Facultad de Ciencias, Universidad Autónoma de Madrid, Campus
de Cantoblanco, Madrid 28049, Spain
Received 28 November 2005; Revised 16 December 2005; Accepted 3 January 2006
Copyright © 2006 J. Avila et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
- S B Prusiner, “Shattuck lecture—neurodegenerative diseases and prions,” The New England Journal of Medicine, vol. 344, no. 20, pp. 1516–1526, 2001.
- M Sadqi, F Hernández, U Pan, et al., “Alpha-helix structure in Alzheimer's disease aggregates of tau-protein,” Biochemistry, vol. 41, no. 22, pp. 7150–7155, 2002.
- M Arrasate, S Mitra, E S Schweitzer, M R Segal, and S Finkbeiner, “Inclusion body formation reduces levels of mutant huntingtin and the risk of neuronal death,” Nature, vol. 431, no. 7010, pp. 805–810, 2004.
- V T Marchesi, “An alternative interpretation of the amyloid Abeta hypothesis with regard to the pathogenesis of Alzheimer's disease,” Proceedings of the National Academy of Sciences of the United States of America, vol. 102, no. 26, pp. 9093–9098, 2005.
- N F Bence, R M Sampat, and R R Kopito, “Impairment of the ubiquitin-proteasome system by protein aggregation,” Science, vol. 292, no. 5521, pp. 1552–1555, 2001.
- G Merlini and V Bellotti, “Molecular mechanisms of amyloidosis,” The New England Journal of Medicine, vol. 349, no. 6, pp. 583–596, 2003.
- C A Ross and M A Poirier, “Protein aggregation and neurodegenerative disease,” Nature Medicine, vol. 10, no. suppl, pp. S10–S17, 2004.
- J Avila, J J Lucas, M Pérez, and F Hernández, “Role of tau protein in both physiological and pathological conditions,” Physiological Reviews, vol. 84, no. 2, pp. 361–384, 2004.
- R A Crowther, O F Olesen, R Jakes, and M Goedert, “The microtubule binding repeats of tau protein assemble into filaments like those found in Alzheimer's disease,” FEBS Letters, vol. 309, no. 2, pp. 199–202, 1992.
- E Montejo de Garcini, L Serrano, and J Avila, “Self assembly of microtubule associated protein tau into filaments resembling those found in Alzheimer disease,” Biochemical and Biophysical Research Communications, vol. 141, no. 2, pp. 790–796, 1986.
- M Pérez, J M Valpuesta, M Medina, E Montejo de Garcini, and J Avila, “Polymerization of tau into filaments in the presence of heparin: the minimal sequence required for tau-tau interaction,” Journal of Neurochemistry, vol. 67, no. 3, pp. 1183–1190, 1996.
- H Wille, G Drewes, J Biernat, E M Mandelkow, and E Mandelkow, “Alzheimer-like paired helical filaments and antiparallel dimers formed from microtubule-associated protein tau in vitro,” The Journal of Cell Biology, vol. 118, no. 3, pp. 573–584, 1992.
- I Santa-María, F Hernández, M A Smith, G Perry, J Avila, and F J Moreno, “Neurotoxic dopamine quinone facilitates the assembly of tau into fibrillar polymers,” Molecular and Cellular Biochemistry, vol. 278, no. 1-2, pp. 203–212, 2005.
- W M van Roon-Mom, S J Reid, R L Faull, and R G Snell, “TATA-binding protein in neurodegenerative disease,” Neuroscience, vol. 133, no. 4, pp. 863–872, 2005.
- D C David, R Layfield, L Serpell, Y Narain, M Goedert, and M G Spillantini, “Proteasomal degradation of tau protein,” Journal of Neurochemistry, vol. 83, no. 1, pp. 176–185, 2002.
- N Sahara, M Murayama, T Mizoroki, et al., “In vivo evidence of CHIP up-regulation attenuating tau aggregation,” Journal of Neurochemistry, vol. 94, no. 5, pp. 1254–1263, 2005.
- G V Johnson, R S Jope, and L I Binder, “Proteolysis of tau by calpain,” Biochemical and Biophysical Research Communications, vol. 163, no. 3, pp. 1505–1511, 1989.
- H Shimura, D Schwartz, S P Gygi, and K S Kosik, “CHIP-Hsc70 complex ubiquitinates phosphorylated tau and enhances cell survival,” The Journal of Biological Chemistry, vol. 279, no. 6, pp. 4869–4876, 2004.
- P J Kahle and C Haass, “How does parkin ligate ubiquitin to Parkinson's disease?,” EMBO Reports, vol. 5, no. 7, pp. 681–685, 2004.
- M S Gentry, C A Worby, and J E Dixon, “Insights into Lafora disease: malin is an E3 ubiquitin ligase that ubiquitinates and promotes the degradation of laforin,” Proceedings of the National Academy of Sciences of the United States of America, vol. 102, no. 24, pp. 8501–8506, 2005.
- T C Gamblin, R W Berry, and L I Binder, “Tau polymerization: role of the amino terminus,” Biochemistry, vol. 42, no. 7, pp. 2252–2257, 2003.
- T C Gamblin, R W Berry, and L I Binder, “Modeling tau polymerization in vitro: a review and synthesis,” Biochemistry, vol. 42, no. 51, pp. 15009–15017, 2003.
- T C Gamblin, M E King, H Dawson, et al., “In vitro polymerization of tau protein monitored by laser light scattering: method and application to the study of FTDP-17 mutants,” Biochemistry, vol. 39, no. 20, pp. 6136–6144, 2000.
- T C Gamblin, M E King, J Kuret, R W Berry, and L I Binder, “Oxidative regulation of fatty acid-induced tau polymerization,” Biochemistry, vol. 39, no. 46, pp. 14203–14210, 2000.
- I Grundke-Iqbal, K Iqbal, Y C Tung, M Quinlan, H M Wisniewski, and L I Binder, “Abnormal phosphorylation of the microtubule-associated protein tau (tau) in Alzheimer cytoskeletal pathology,” Proceedings of the National Academy of Sciences of the United States of America, vol. 83, no. 13, pp. 4913–4917, 1986.
- M D Ledesma, P Bonay, C Colaço, and J Avila, “Analysis of microtubule-associated protein tau glycation in paired helical filaments,” The Journal of Biological Chemistry, vol. 269, no. 34, pp. 21614–21619, 1994.
- C M Wischik, R YK Lai, and C R Harrington, “Modelling prion-like processing of tau protein in Alzheimer's disease for pharmaceutical development,” in Brain Microtubule Associated Proteins: Modification in Disease, J Avila, R Brandt, and K S Kosik, Eds., pp. 185–241, Harwood Academic, Chur, Switzerland, 1997.
- M Pérez, M Arrasate, E Montejo de Garcini, V Munoz, and J Avila, “In vitro assembly of tau protein: mapping the regions involved in filament formation,” Biochemistry, vol. 40, no. 20, pp. 5983–5991, 2001.
- I Santa-María, F Hernández, C P Martin, J Avila, and F J Moreno, “Quinones facilitate the self-assembly of the phosphorylated tubulin binding region of tau into fibrillar polymers,” Biochemistry, vol. 43, no. 10, pp. 2888–2897, 2004.
- W Noble, E Planel, C Zehr, et al., “Inhibition of glycogen synthase kinase-3 by lithium correlates with reduced tauopathy and degeneration in vivo,” Proceedings of the National Academy of Sciences of the United States of America, vol. 102, no. 19, pp. 6990–6995, 2005.
- M Pérez, F Hernández, F Lim, J Diaz-Nido, and J Avila, “Chronic lithium treatment decreases mutant tau protein aggregation in a transgenic mouse model,” Journal of Alzheimer's Disease, vol. 5, no. 4, pp. 301–308, 2003.
- I E Vega, L Cui, J A Propst, M L Hutton, G Lee, and S H Yen, “Increase in tau tyrosine phosphorylation correlates with the formation of tau aggregates,” Brain Research. Molecular Brain Research, vol. 138, no. 2, pp. 135–144, 2005.
- K Duff and E Planel, “Untangling memory deficits,” Nature Medicine, vol. 11, no. 8, pp. 826–827, 2005.
- F Lim, F Hernández, J J Lucas, P Gomez-Ramos, M A Moran, and J Avila, “FTDP-17 mutations in tau transgenic mice provoke lysosomal abnormalities and Tau filaments in forebrain,” Molecular and Cellular Neuroscience, vol. 18, no. 6, pp. 702–714, 2001.
- F Hernández, R Cuadros, and J Avila, “Zeta 14-3-3 protein favours the formation of human tau fibrillar polymers,” Neuroscience Letters, vol. 357, no. 2, pp. 143–146, 2004.
- M A Lovell and W R Markesbery, “Ectopic expression of Musashi-1 in Alzheimer disease and Pick disease,” Journal of Neuropathology and Experimental Neurology, vol. 64, no. 8, pp. 675–680, 2005.
- P J Lu, G Wulf, X Z Zhou, P Davies, and K P Lu, “The prolyl isomerase Pin1 restores the function of Alzheimer-associated phosphorylated tau protein,” Nature, vol. 399, no. 6738, pp. 784–788, 1999.
- M Poli, L B Gatta, R Dominici, et al., “DNA sequence variations in the prolyl isomerase Pin1 gene and Alzheimer's disease,” Neuroscience Letters, vol. 389, no. 2, pp. 66–70, 2005.
- V M Lee, M Goedert, and J Q Trojanowski, “Neurodegenerative tauopathies,” Annual Review of Neuroscience, vol. 24, pp. 1121–1159, 2001.
- S C Feinstein and L Wilson, “Inability of tau to properly regulate neuronal microtubule dynamics: a loss-of-function mechanism by which tau might mediate neuronal cell death,” Biochimica et Biophysica Acta, vol. 1739, no. 2-3, pp. 268–279, 2005.
- M Goedert, S Satumtira, R Jakes, et al., “Reduced binding of protein phosphatase 2A to tau protein with frontotemporal dementia and parkinsonism linked to chromosome 17 mutations,” Journal of Neurochemistry, vol. 75, no. 5, pp. 2155–2162, 2000.
- R Brandt, M Hundelt, and N Shahani, “Tau alteration and neuronal degeneration in tauopathies: mechanisms and models,” Biochimica et Biophysica Acta, vol. 1739, no. 2-3, pp. 331–354, 2005.
- C Andorfer, C M Acker, Y Kress, P R Hof, K Duff, and P Davies, “Cell-cycle reentry and cell death in transgenic mice expressing nonmutant human tau isoforms,” The Journal of Neuroscience, vol. 25, no. 22, pp. 5446–5454, 2005.
- H G Lee, G Perry, P I Moreira, et al., “Tau phosphorylation in Alzheimer's disease: pathogen or protector?,” Trends in Molecular Medicine, vol. 11, no. 4, pp. 164–169, 2005.
- P V Arriagada, J H Growdon, E T Hedley-Whyte, and B T Hyman, “Neurofibrillary tangles but not senile plaques parallel duration and severity of Alzheimer's disease,” Neurology, vol. 42, no. 3 pt 1, pp. 631–639, 1992.
- H Braak and E Braak, “Neuropathological stageing of Alzheimer-related changes,” Acta Neuropathologica (Berl), vol. 82, no. 4, pp. 239–259, 1991.
- A Alzheimer, “Über eigenartige Krankheitsfälle des späteren Alters,” Zeitschrift für die gesamte Neurologie und Psychiatrie, vol. 4, pp. 356–385, 1911.
- P Cras, M A Smith, P L Richey, S L Siedlak, P Mulvihill, and G Perry, “Extracellular neurofibrillary tangles reflect neuronal loss and provide further evidence of extensive protein cross-linking in Alzheimer disease,” Acta Neuropathologica (Berl), vol. 89, no. 4, pp. 291–295, 1995.
- Y Fukutani, K Kobayashi, I Nakamura, K Watanabe, K Isaki, and N J Cairns, “Neurons, intracellular and extracellular neurofibrillary tangles in subdivisions of the hippocampal cortex in normal ageing and Alzheimer's disease,” Neuroscience Letters, vol. 200, no. 1, pp. 57–60, 1995.
- W Bondareff, C Q Mountjoy, M Roth, and D L Hauser, “Neurofibrillary degeneration and neuronal loss in Alzheimer's disease,” Neurobiology of Aging, vol. 10, no. 6, pp. 709–715, 1989.
- M Goedert, “Filamentous nerve cell inclusions in neurodegenerative diseases: tauopathies and alpha-synucleinopathies,” Philosophical Transactions of the Royal Society of London. Series B, Biological Sciences, vol. 354, no. 1386, pp. 1101–1118, 1999.
- R Morsch, W Simon, and P D Coleman, “Neurons may live for decades with neurofibrillary tangles,” Journal of Neuropathology and Experimental Neurology, vol. 58, no. 2, pp. 188–197, 1999.
- K Santacruz, J Lewis, T Spires, et al., “Tau suppression in a neurodegenerative mouse model improves memory function,” Science, vol. 309, no. 5733, pp. 476–481, 2005.
- B Caughey and P T Lansbury, “Protofibrils, pores, fibrils, and neurodegeneration: separating the responsible protein aggregates from the innocent bystanders,” Annual Review of Neuroscience, vol. 26, pp. 267–298, 2003.
- T D Bird, D Nochlin, P Poorkaj, et al., “A clinical pathological comparison of three families with frontotemporal dementia and identical mutations in the tau gene (P301L),” Brain, vol. 122, no. pt 4, pp. 741–756, 1999.
- A Delacourte, J P David, N Sergeant, et al., “The biochemical pathway of neurofibrillary degeneration in aging and Alzheimer's disease,” Neurology, vol. 52, no. 6, pp. 1158–1165, 1999.
- T Gomez-Isla, R Hollister, H West, et al., “Neuronal loss correlates with but exceeds neurofibrillary tangles in Alzheimer's disease,” Annals of Neurology, vol. 41, no. 1, pp. 17–24, 1997.